Genetic Technologies Stock Today
| GENE Stock | USD 0.77 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 82
|
Genetic Technologies is trading at 0.77 as of the 22nd of November 2024, a No Change since the beginning of the trading day. The stock's lowest day price was 0.77. Genetic Technologies has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Genetic Technologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of August 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage peoples health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company has 4.85 M outstanding shares of which 25.84 K shares are currently shorted by private and institutional investors with about 2.32 trading days to cover. More on Genetic Technologies
Moving against Genetic Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genetic Stock Highlights
| Old Name | Invictus MD Strategies Corp |
| Business Concentration | Pharmaceutical Products, Diagnostics & Research, Healthcare, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) |
Genetic Technologies (GENE) is traded on NASDAQ Exchange in USA. It is located in 321 Chapel Street, Prahran, VIC, Australia, 3181 and employs 55 people. Genetic Technologies is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.71 M. Genetic Technologies conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 4.85 M outstanding shares of which 25.84 K shares are currently shorted by private and institutional investors with about 2.32 trading days to cover.
Genetic Technologies currently holds about 11.74 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Check Genetic Technologies Probability Of Bankruptcy
Ownership AllocationRoughly 98.9 (percent) of Genetic Technologies outstanding shares are held by general public with 1.1 pct. by outside corporations.
Check Genetic Ownership Details
Genetic Technologies Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Genetic Technologies market risk premium is the additional return an investor will receive from holding Genetic Technologies long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (23.94) |
Genetic Stock Against Markets
Genetic Technologies Corporate Management
| Kevin Camilleri | Chief EasyDNA | Profile | |
| CPA BCom | Chief Secretary | Profile | |
| AGIA BCom | CFO Sec | Profile | |
| Bus FCI | Consultant | Profile | |
| Simon Morriss | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.